Keytruda Immunotherapy for Treatment of Liver Cancer

(November 13, 2018)

According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib), (1) and has not... Continue Reading


U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma

(November 12, 2018)

The U.S. Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least... Continue Reading


Lorbrena Approved for second- or third-line treatment of ALK-positive metastatic NSCLC

(November 8, 2018)

The US Food and Drug Administration granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on (Xalkori... Continue Reading


FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

(November 5, 2018)

On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed... Continue Reading


20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer

(October 31, 2018)

Adjuvant high-dose chemotherapy (HDCT) with hematopoietic stem cell transplant (HSCT) may be beneficial for patients with breast cancer and more than 9 involved axially lymph nodes (ALN), according to a study presented at the 2018 ESMO Congress in Munich,... Continue Reading


New Treatment Approved for Influenza

(October 26, 2018)

The Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in patients aged ≥12 years old who have been symptomatic for no more than 48 hours. Xofluza is a first-in-class, single-dose... Continue Reading


November Is National Lung Cancer Awareness Month

(October 23, 2018)

Treatment advances – lung cancer resources and advocacy are making the difference The month of November brings lung cancer into focus. Over the past few years great strides have been made in the treatment of non-small cell lung cancer due to the... Continue Reading


Laurie MacCaskill Partners with CancerConnect

(October 19, 2018)

KETCHUM – LOS ANGELES: Laurie MacCaskill, a 12-year survivor of pancreatic cancer and former chair of the Pancreatic Cancer Action Network has announced a newly established partnership with Cancer Connect to support pancreatic cancer patients with information,... Continue Reading


Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone

(October 15, 2018)

Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable... Continue Reading


More women with early-stage breast cancer may be able to avoid chemotherapy

(October 10, 2018)

Results from a large clinical trial called TAILORx showed that more women with early-stage breast cancer may now be able to avoid chemotherapy after surgery. The women who participated in the study had hormone receptor-positive, HER2-negative, axillary... Continue Reading


Designation for Advanced Cutaneous Squamous Cell Carcinoma

(October 1, 2018)

Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma The U.S. Food and Drug Administration (FDA) has approved cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with... Continue Reading


duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

(September 25, 2018)

The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In... Continue Reading


Next Page »